Table 4.

In vitro antifungal susceptibility of 1539 clinical C. albicans and C. glabrata isolates from VVC and RVVC as determined by the CLSI method

		AmB	FLU	NYS	TEB	AFG	CFG	MFG	BUC	CLO	FLC	ITC	MIC	TEC	VRC
C. albicans
VVC	Range	0.15–32	0.030–128	0.03–32	0.03–256	0.008–0.5	0.008–0.5	0.008–0.5	0.015–32	0.015–32	0.06–128	0.015–32	0.015–32	0.015–32	0.015–8
	GM	0.21	0.65	1.55	39.23	0.02	0.1	0.03	0.11	0.05	0.74	0.09	0.27	0.12	0.06
	MIC90	0.5	4	8	256	0.03	0.25	0.25	1	0.25	4	1	4	2	0.5
RVVC	Range	0.015–32	0.06–128	0.03–32	0.25–256	0.008–0.25	0.008–0.5	0.008–0.5	0.015–8	0.015–16	0.06–64	0.015–32	0.015–32	0.015–32	0.015–8
	GM	0.25	0.94	1.82	74.50	0.01	0.1	0.03	0.13	0.05	1.03	0.10	0.46	0.33	0.09
	MIC90	0.6	4	8	256	0.015	0.25	0.06	1	0.5	4	0.5	8	8	0.5
	P	0.813	0.435	0.770	0	0.242	0.7	0.566	0.736	0.341	0.14	0.041	0.053	0	0.34
C. glabrata
VVC	Range	0.03–2	0.06–16	0.03–32	0.25–256	0.015–0.5	0.008–0.5	0.008–0.5	0.015–16	0.015–16	0.125–128	0.015–32	0.015–16	0.015–32	0.015–32
	GM	0.33	0.18	3.88	40.63	0.03	0.06	0.05	0.24	0.23	1.68	0.42	0.25	0.15	0.09
	MIC90	1	1	8	256	0.06	0.25	0.25	1	1	8	4	2	1	0.25
RVVC	Range	0.03–2	0.06–2	0.03–16	0.25–256	0.008–0.06	0.008–0.5	0.008–0.5	0.015–8	0.03–4	0.125–128	0.03–32	0.03–32	0.015–32	0.015–32
	GM	0.20	0.17	2.31	8.86	0.02	0.06	0.04	0.16	0.134	1.03	0.29	0.27	0.17	0.11
	MIC90	0.5	1	8	256	0.03	0.25	0.25	1	1	16	2	4	2	0.5
	P	0.017	0.366	0.035	0.015	0.058	0.68	0.78	0.87	0.25	0.1	1	0.043	0.683	0.293

Note: GM geometry mean, BUC butoconazole, CLO Clotrimazole, FLC Fluconazole, ITC Itraconazole, VRC Voriconazole, MIC Miconazole, TEC Terconazole, AmB Amphotericin B, FLU Flucytosine, NYS Nystatin, TEB Terbinafine, AFG Anidulafungin, CFG Caspofungin, MFG Micafungin. The MIC GM value of C. albicans for Itraconazole, Terconazole, and Terbinafine in RVVC is higher than those in VVC. The MIC GM value of C. glabrata for Miconazole, Amphotericin B, Nystatin, Caspofungin, and Terbinafine in RVVC is higher than those in VVC